Clinical trials: Plasma Cell Tumor
Multiple Myeloma
GEM05 for Patients With Multiple Myeloma Under 65 Years
The primary objective is to compare safety and efficacy of three induction treatments: VBMCP-VBAD / Velcade versus Thalidomide / Dexamethasone versus Velcade / Thalidomide / Dexamethasone.
- Trial name
- GEM05MENOS65 (NCT00461747)
- Testing
- VBMCP/VBAD/Velcade, Thalidomide/Dexamethasone, Velcade/Thalidomide/Dexamethasone
- Where
- 79 sites in Spain
- Volunteers
- 390 people
- Sponsor
- PETHEMA Foundation
Multiple Myeloma
A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma
The purpose of this Phase 2 randomized study is to evaluate the efficacy and safety of treatment with a regimen of VELCADE, dexamethasone, and thalidomide (VDT) or VELCADE, dexamethasone, thalidomide, and cyclophosphamide (VDTC)…
- Trial name
- NCT00531453
- Testing
- bortezomib, dexamethasone, and thalidomide, bortezomib, dexamethasone, thalidomide, and cyclophosphamide
- Where
- Austria
- Volunteers
- 98 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Oropharyngeal Cancer, HPV-Related Carcinoma
A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC)
The researchers think that a blood test (NavDx®) may be able to identify cancer early by looking for circulating DNA from Human Papillomavirus/HPV. Circulating DNA are small pieces of genes that are released into the bloodstream.
- Conditions
- Oropharyngeal Cancer, HPV-Related Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT05814549
- Testing
- NavDx
- Where
- 7 sites in United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma and Plasma Cell Neoplasm
Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of suramin in treating patients who have refractory or…
- Trial name
- NCT00002652
- Testing
- suramin
- Where
- United States
- Sponsor
- University of Arkansas
Relapsed/Refractory Multiple Myeloma
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
The purpose of this study is to determine the overall response rate of patients with Multiple Myeloma to the combination of Daratumumab, Ixazomib, Pomalidomide and Dexamethasone.
- Trial name
- NCT03590652
- Testing
- Ixazomib, Pomalidomide, Dexamethasone
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- University of California, San Diego
Prostatic Neoplasms, Multiple Myeloma
Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies
This study will test the safety, tolerance, and efficacy of different doses of oral gallium maltolate. Patients will receive oral gallium maltolate twice daily for 28-consecutive days followed by 14 days off treatment.
- Conditions
- Prostatic Neoplasms, Multiple Myeloma, Bladder Neoplasms, Lymphoma
- Trial name
- NCT00050687
- Testing
- Gallium maltolate
- Where
- 5 sites in United States
- Sponsor
- Titan Pharmaceuticals
Plasma Cell Myeloma, Multiple Myeloma
Collection of Transplant Stem Cells for Plasma Cell Myeloma
Background: One beneficial treatment for plasma cell myeloma is high-dose chemotherapy followed by stem cell transplant. Researchers want to collect stem cells from the blood for later transplant.
- Trial name
- NCT01547806
- Testing
- Filgrastim, Plerixafor, Apheresis
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
RATIONALE: Antiemetic drugs, such as aprepitant, ondansetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients undergoing a stem cell transplant.
- Trial name
- NCT00248547
- Testing
- aprepitant, dexamethasone, ondansetron
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- OHSU Knight Cancer Institute
Multiple Myeloma
Early Patient Access Treatment Use Protocol CA204-220
The objective of this expanded access program is to provide treatment with elotuzumab in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma at Japanese sites where licensed…
- Trial name
- NCT02856438
- Testing
- Elotuzumab, Lenalidomide, Dexamethasone
- Where
- 4 sites in Japan
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma
RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
The purpose of this research study is to determine the highest dose of lenalidomide and RAD001 that can be given without causing too many serious side effects.
- Trial name
- NCT00729638
- Testing
- RAD001, lenalidomide
- Where
- 5 sites in United States
- Volunteers
- 28 people
- Sponsor
- Massachusetts General Hospital
Multiple Myeloma
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
This is a national, multicenter, open-label, randomized, comparative study designed to compare, first, the TTP of the two treatment schemes proposed (MPV followed by Rd or MPV alternating with Rd) in newly diagnosed MM patients…
- Trial name
- NCT01237249
- Testing
- Melphalan, Prednisone, Velcade
- Where
- 63 sites in Spain
- Volunteers
- 250 people
- Sponsor
- PETHEMA Foundation
Multiple Myeloma
Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma
Multiple myeloma is a kind of hematological malignancy caused by the proliferation of malignant clonal plasma cells. In recent years, the emergence of new therapeutic drugs such as bortezomib and lenalidomide has significantly…
- Trial name
- NCT04186052
- Testing
- BCMA-CART cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anemia, Multiple Myeloma
Adjuvant I.V. Iron Therapy During Erythropoetin Treatment of Anemic Patients With Lymphoproliferative Disorders.
This is a multi-center open label, randomized phase-3 study with stratification according to diagnosis and baseline serum-EPO level.
- Conditions
- Anemia, Multiple Myeloma, Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT00145652
- Testing
- Neo-Recormon and Venofer
- Where
- Sweden
- Volunteers
- 66 people
- Sponsor
- Sundsvall Hospital
Diffuse Large B Cell Lymphoma, Multiple Myeloma
Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
Pivotal study to validate the diagnostic performance of PointCheck, the first non invasive device to preliminary detect neutropenia in cancer patients receiving intermediate/high risk antineoplastic therapy.
- Trial name
- PC002 (NCT06323447)
- Testing
- PointCheck
- Where
- 6 sites in United States, Spain
- Volunteers
- 210 people
- Sponsor
- Leuko Labs, Inc.
Multiple Myeloma
Home Treatment With Carfilzomib in Patients With Multiple Myeloma
New treatment regimens with increased efficiency and reduced toxicities are being introduced in the treatment of Multiple Myeloma (MM).
- Trial name
- NCT05620238
- Testing
- Carfilzomib
- Where
- Denmark
- Volunteers
- 9 people
- Sponsor
- Thomas Lund
Multiple Myeloma
Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients
The purpose of this study is to compare a standard chemotherapy regimen of cyclophosphamide, dexamethasone plus thalidomide with a newer regimen of cyclophosphamide, dexamethasone plus lenalidomide with or without carfilzomib.
- Trial name
- Myeloma XI (NCT01554852)
- Testing
- Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen, Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen, Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen
- Where
- United Kingdom
- Volunteers
- 4,420 people
- Sponsor
- University of Leeds
Peripheral T-cell Lymphoma, NK/T-Cell Lymphoma
Circulating Tumor DNA in Peripheral T-cell Lymphomas
The aim of this study is to evaluate the feasibility of circulating tumor DNA (ctDNA) measurement in blood plasma for the applicability in prognostication, treatment evaluation and measurable residual disease (MRD) surveillance…
- Trial name
- CIRCULATE (NCT06362148)
- Testing
- Tumor- and plasma-informed, next-generation sequencing (NGS)-based patient-specific droplet digital (dd)PCR assay, 18F-fludeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT)
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- University of Aarhus
Multiple Myeloma and Plasma Cell Neoplasm, Pain
Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain
RATIONALE: Radioactive drugs, such as samarium Sm 153 lexidronam pentasodium, may carry radiation directly to cancer cells and not harm normal cells.
- Trial name
- NCT00482378
- Testing
- Pamidronate, Zoledronic acid, Sm 153 lexidronam
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Mayo Clinic
Multiple Myeloma, Multiple Myeloma Without Mention of Remission
Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma
All4Cure is partnering with community oncology practices participating in the Quality Cancer Care Alliance (QCCA) and Exigent Research to develop a clinical pathway that standardizes the evaluation, treatment and ongoing…
- Trial name
- NCT06149910
- Testing
- Multiple Myeloma Pathway, All4Cure Platform, Documentation Pathway
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- All4Cure
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study
This clinical trial tests whether a geriatric optimization plan (GO!) works to improve survival in patients over 60 with a hematologic malignancy or bone marrow failure syndrome eligible for allogeneic hematopoietic cell…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT05972577
- Testing
- Health Promotion and Education, Medical Device Usage and Evaluation, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.